News

Shahab Moossavi, MD, FACC Concord Hospital Cardiovascular Institute, Concord, New Hampshire Introduction Aortic valvar stenosis is a common diagnosis in cardiology practices across the United States. For symptomatic patients with severe aortic valvar stenosis, 2 treatment options are available and include surgical aortic valve replacement and transcatheter aortic valve replacement. As these patients are more […]

Radial access has been shown to improve outcome by not only lowering the risk of bleeding during coronary intervention, but also by improving mortality in STEMI patients. Dealing with tortuous arteries requires a level of experience that can be obtained by using radial access in older female patients during elective cases and building a protocol […]

As the advancements of catheter-based technology continue to evolve, the use of large bore access is growing to accommodate different procedures. In doing so, it cannot go unspoken that the operator must recognize the burden of postprocedural vascular access closure complications and their burden on the hospital, the patient, and the cost of care.

More than 100 operators from 50 countries have teamed up to develop a unique algorithm for crossing chronic total occlusion (CTO) lesions, with the aim of standardizing techniques and helping operators learn how to manage these difficult-to-treat lesions.

Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz comparing use of the EkoSonic Endovascular System in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk […]

Economic analyses from the WRAP-IT study, sponsored by Medtronic, demonstrate the Tyrx cardiac absorbable antibacterial envelope’s (Tyrx Envelope) cost effectiveness in European markets for patients at increased risk of infections.

New research from the ISAR-REACT 5 trial indicated that patients with ACS who received PCI had a lower composite endpoint of all-cause death, MI or stroke when given prasugrel vs. ticagrelor therapy.

As physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer’s disease approved in 18 years, patients want to know: “Will this medication help me — and how much?”

Case Presentation: Endomyocardial fibrosis is an unusual etiology of heart failure. A detailed evaluation of diastolic function is key for diagnosis. The presence of fibrosis generates key functional alterations in the diagnosis. Multimodality imaging helps to establish severity and functional compromise.